SCM
LVTX

Silverarc Capital Management’s LAVA Therapeutics LVTX Stock Holding History

Silverarc Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-140,291
Closed -$233K – 90
2023
Q1 		$233K Sell
140,291
-297,471
-68% -$833K 0.1% 68
2022
Q4 		$1.53M Sell
437,762
-173,047
-28% -$794K 0.44% 57
2022
Q3 		$2.79M Buy
+610,809
New +$1.68M 0.94% 37

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Silverarc Capital Management's LVTX Position: Q2 2023 in Review

Silverarc Capital Management sold out of LAVA Therapeutics (LVTX) in Q2 2023, closing a stake of 140,291 shares — an estimated $233K sold.

Silverarc Capital Management first reported a position in LVTX in Q3 2022 and held it in 3 quarters. The position peaked at $2.79M in Q3 2022. 15 funds tracked by Wall St. Rank hold LVTX as of Q2 2023.

  • Silverarc Capital Management reported no remaining LAVA Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 140,291 LAVA Therapeutics shares in Q2 2023, an estimated $233K.
  • Silverarc Capital Management first reported a position in LAVA Therapeutics in Q3 2022 and held it in 3 quarters.
  • Silverarc Capital Management's LAVA Therapeutics position peaked at $2.79M in Q3 2022.
  • 15 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2023.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.